NSTI trials effective

Israel’s Atox Bio announced the success of Phase Iia clinical trials of its AB103 treatment of Necrotizing Soft Tissue Infections (NSTI). NSTIs are life-threatening bacterial infections with significant morbidity and high mortality rate.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *